GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » EPS (Diluted)

Alseres Pharmaceuticals (Alseres Pharmaceuticals) EPS (Diluted) : $-100.00 (TTM As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals EPS (Diluted)?

Alseres Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2014 was $-50.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2014 was $-100.00.

Alseres Pharmaceuticals's EPS (Basic) for the three months ended in Jun. 2014 was $-50.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2014 was $-100.00.

Alseres Pharmaceuticals's EPS without NRI for the three months ended in Jun. 2014 was $-50.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2014 was $-96.26.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Alseres Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for Alseres Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals EPS (Diluted) Chart

Alseres Pharmaceuticals Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,300.00 - -500.00 -300.00 -150.00

Alseres Pharmaceuticals Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -100.00 -50.00 50.00 -50.00 -50.00

Competitive Comparison of Alseres Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, Alseres Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alseres Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alseres Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Alseres Pharmaceuticals's PE Ratio falls into.



Alseres Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Alseres Pharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2013 is calculated as

Diluted EPS (A: Dec. 2013 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.942-0)/0.006
=-157.00

Alseres Pharmaceuticals's Diluted EPS for the quarter that ended in Jun. 2014 is calculated as

Diluted EPS (Q: Jun. 2014 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.321-0)/0.006
=-53.50

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-100.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alseres Pharmaceuticals  (OTCPK:ALSE) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Alseres Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466
Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.
Executives
Mark Jerome Pykett officer: President and COO 223A MAIN ST, BOXFORD MA 021921
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Peter G Savas director, officer: Chief Executive Officer 110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston director C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr officer: Exec VP of Fin & Admin & CFO C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon officer: Chief Financial Officer 1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck director P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines